Deep Analysis and Strategic Insights: The Impact of Vice President Yu Bing’s Departure on BCHT Biotechnology
In a move that has sent ripples through China’s vaccine industry, Changchun BCHT Biotechnology Co.,...
SHA: 688276
Changchun BCHT Partners with Baosight Software for Biopharmaceutical Digitization
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced a partnership with compatriot firm...
Changchun BCHT Biotechnology Receives NMPA Approval for HSV-2 mRNA Vaccine LVRNA101
Changchun BCHT Biotechnology Co., Ltd (SHA: 688276), a China-based biotechnology company, has announced receiving clinical...
Changchun BCHT Secures NMPA Approval for Freeze-Dried Human Rabies Vaccine Trials
Changchun BCHT Biotechnology Co., Ltd. (SHA: 688276), based in China, has announced that it has...
Changchun BCHT Biotechnology Receives NMPA Approval for Anti-Tetanus Monoclonal Antibody Injection
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced that it has received clinical...
Changchun BCHT Biotechnology Invests in Influenza Vaccine Production Expansion
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced plans to invest RMB 805...
Changchun BCHT Biotechnology to Acquire Full Stake in mRNA R&D Firm Transcend Biomedical
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced its intention to invest in...
Changchun BCHT Biotechnology and IMB CAMS Enter Five-Year Research Pact
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced a five-year scientific research cooperation...
Changchun BCHT Gains NMPA Approval for Herpes Zoster Vaccine
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced receiving marketing approval from the...